Joo-Won Lee’s research while affiliated with University of Southern California and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (3)


Obesity and low testosterone interact to increase vulnerability to Alzheimer's disease pathogenesis
  • Article

July 2013

·

4 Reads

·

1 Citation

Joo-Won Lee

·

Emily Rosario

·

Anusha Jayaraman

·


Ligand for translocator protein increases hippocampal expression of glial beta-amyloid scavenger receptors and reduces beta-amyloid in male mice and rats
  • Article
  • Full-text available

July 2013

·

31 Reads

·

Anusha Jayaraman

·

Joo-Won Lee

·

[...]

·

Download

Figure 1. Ro5-4864 reduces A ␤ accumulation in the hippocampus of 3xTgAD mice. A–J , Representative photomicrographs show A ␤ immunoreactivity in hippocampus CA1 ( A–E ) and subiculum ( F–J ) regions of 7-month-old 3xTgAD mice in the sham ϩ vehicle ( A , F ), GDX ϩ vehicle ( B , G ), and GDX ϩ Ro5-4864 ( C , H ) conditions; and 24-month-old 3xTgAD mice administered vehicle ( D , I ) and Ro5-4864 ( E , J ). Data show mean A ␤ immunoreactivity loads ( Ϯ SEM) in 3xTgAD mice at ages 7 months (solid bars, left axis) and 24 months (open bars, right axis) in hippocampus CA1 ( K ) and subiculum ( L ). * p Ͻ 0.05, compared with all other groups. 
Figure 2. Ro5-4864 reduces hippocampal gliosis in 3xTgAD mice. A-J, Representative photomicrographs show GFAP (A-E) and IBA-1 (F-J ) immunoreactivities in the hippocampus CA1 region of 7-month-old 3xTgAD mice in the sham vehicle (A, F ), GDX vehicle (B, G), and GDX Ro5-4864 (C, H ) conditions; and 24-month-old 3xTgAD mice administered vehicle (D, I ) and Ro5-4864 (E, J ). K, GFAP immunoreactivity volume density values (SEM) in the hippocampus CA1 region. L, IBA-1 immunoreactivity volume density values (SEM) in the hippocampus CA1 region. # p 0.001, compared with GDX vehicle. *p 0.001, compared with all other groups.
Figure 3. Ro5-4864 regulates brain testosterone and progesterone levels and improves behavioral deficits in 3xTgAD mice. A, Brain testosterone levels were quantified in limbic structures. Ro5-4864 treatment attenuated GDX-induced testosterone depletion in young-adult 7-month-old mice. B, Brain progesterone levels were quantified in limbic structures. Ro5-4864 treatment increased PROG more than twofold in GDX 7-month-old mice. C, Percentage duration (SEM) spent exploring the open arm of the EPM, with increased exploration of the open arm indicative of reduced anxiety. D, SAB, represented as percentage alternation (SEM); both 7-month-old GDX and 24-month-old 3xTgAD mice administered Ro5-4864 exhibited significantly improved SAB performance. # p 0.05, compared with sham vehicle. *p 0.05, compared with all other groups.
Ligand for Translocator Protein Reverses Pathology in a Mouse Model of Alzheimer's Disease

May 2013

·

109 Reads

·

109 Citations

The Journal of Neuroscience : The Official Journal of the Society for Neuroscience

Ligands of the translocator protein (TSPO) elicit pleiotropic neuroprotective effects that represent emerging treatment strategies for several neurodegenerative conditions. To investigate the potential of TSPO as a therapeutic target for Alzheimer's disease (AD), the current study assessed the effects of the TSPO ligand Ro5-4864 on the development of neuropathology in 3xTgAD mice. The effects of the TSPO ligand on neurosteroidogenesis and AD-related neuropathology, including β-amyloid accumulation, gliosis, and behavioral impairment, were examined under both early intervention (7-month-old young-adult male mice with low pathology) and treatment (24-month-old, aged male mice with advanced neuropathology) conditions. Ro5-4864 treatment not only effectively attenuated development of neuropathology and behavioral impairment in young-adult mice but also reversed these indices in aged 3xTgAD mice. Reduced levels of soluble β-amyloid were also observed by the combination of TSPO ligands Ro5-4864 and PK11195 in nontransgenic mice. These findings suggest that TSPO is a promising target for the development of pleiotropic treatment strategies for the management of AD.

Citations (1)


... Translocator protein (TSPO) is a protein of the outer mitochondrial membrane, which has been implicated in numerous central nervous system pathologies [30][31][32][33]. It was initially named the peripheral benzodiazepine receptor (PBR) with the updated nomenclature being adopted to reflect the evolving view that this protein translocates substrates across the outer mitochondrial, a view that nonetheless remains controversial [34]. ...

Reference:

Mitochondrial dysfunction in NPC1-deficiency is not rescued by drugs targeting the glucosylceramidase GBA2 and the cholesterol-binding proteins TSPO and StARD1
Ligand for Translocator Protein Reverses Pathology in a Mouse Model of Alzheimer's Disease

The Journal of Neuroscience : The Official Journal of the Society for Neuroscience